Andreas Nitsche
Overview
Explore the profile of Andreas Nitsche including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
242
Citations
17080
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bodenstein C, Bourquain D, Nitsche A, Grossegesse M
J Med Virol
. 2025 Feb;
97(2):e70246.
PMID: 39977402
Since the global outbreak of Mpox in 2022, interest in seroepidemiological and vaccine studies has grown rapidly. One aspect of interest in these studies is the detection of neutralizing antibodies...
2.
Loyal L, Braun J, Reimer U, Meyer-Arndt L, Henze L, Kruse B, et al.
Cell Rep
. 2025 Feb;
44(2):115314.
PMID: 39960834
Repeated vaccinations and infections have led to diverse states of hybrid immunity against SARS-CoV-2 in the global population. However, age and comorbidities can compromise protection against severe disease, and antibody-mediated...
3.
Hoffmann T, Michel J, Nitsche A, Mache C, Schulze J, Wolff T, et al.
Sci Data
. 2024 Dec;
11(1):1322.
PMID: 39632915
Conventional thin section electron microscopy of viral pathogens, such as the pandemic SARS-CoV-2, can provide structural information on the virus particle phenotype and its evolution. We recorded about 900 transmission...
4.
Marcus U, Michel J, Lunchenkov N, Beslic D, Treindl F, Surtees R, et al.
BMC Infect Dis
. 2024 Oct;
24(1):1211.
PMID: 39468476
No abstract available.
5.
Otieno J, Ruis C, Onoja A, Kuppalli K, Hoxha A, Nitsche A, et al.
Nat Med
. 2024 Oct;
31(1):342-350.
PMID: 39442559
Monkeypox virus (MPXV) is endemic in western and Central Africa, and in May 2022, a clade IIb lineage (B.1) caused a global outbreak outside Africa, resulting in its detection in...
6.
Marcus U, Michel J, Lunchenkov N, Beslic D, Treindl F, Surtees R, et al.
BMC Infect Dis
. 2024 Oct;
24(1):1153.
PMID: 39396951
Introduction: During the mpox outbreak in 2022, the highest number of cases in Germany were registered in Berlin, almost all of them in men who have sex with men (MSM)....
7.
Pathirana S, Deepachandi B, Gunasekara P, Fernando N, Perera I, Gangani D, et al.
Int J Microbiol
. 2024 Sep;
2024:1331067.
PMID: 39346702
COVID-19 serological tests complement the molecular diagnostics and can be used as important tool for serosurveillance and vaccine efficiency evaluation. The aim of this study was to develop and evaluate...
8.
Obermeier P, Plinke C, Brinkmann A, Lachmann R, Melchert J, Corman V, et al.
Emerg Infect Dis
. 2024 Jun;
30(7):1416-1419.
PMID: 38916584
In July 2023, clade IIb-associated mpox reemerged in Germany at low levels, mainly affecting men who have sex with men. We report a representative case and phylogeny of available genome...
9.
Honning A, Tomczyk S, Hermes J, Grossegesse M, Hofmann N, Michel J, et al.
BMC Infect Dis
. 2024 Apr;
24(1):436.
PMID: 38658874
Background: Studies have shown that Omicron breakthrough infections can occur at higher SARS-CoV-2 antibody levels compared to previous variants. Estimating the magnitude of immunological protection induced from COVID-19 vaccination and...
10.
Diaz-Canova D, Moens U, Brinkmann A, Nitsche A, Okeke M
Front Immunol
. 2024 Apr;
15:1277447.
PMID: 38633245
Modified vaccinia virus Ankara (MVA) has been widely tested in clinical trials as recombinant vector vaccine against infectious diseases and cancers in humans and animals. However, one biosafety concern about...